Pairing of applicants’ CJM with university profile in digital environment as a management task

The work is devoted to the application of the Customer Journey Map (CJM) for university applicants and managerial tasks of adapting the profile of the university in the digital environment to the trajectories of the consumer. The author’s definition of the “profile of the university in the digital environment” concept is offered, the analysis of statistical data of university websites is made. The combination of classical studies of applicants’ motivation and factors influencing enrollment in a particular university with modern methods of studying consumer behavior in the digital environment allows to increase the effectiveness of the admission campaign. Customer Journey Map as an analysis tool, in conjunction with the data of network traffic allows to optimize all types of communications of the university and provide its management with necessary information when making managerial decisions. The research revealed an insignificant influence of the university social networks and thematic groups on the decision to enroll to a particular university, which what caused a deeper study of visitors’ behavior on the university websites. Internet traffic activity for a number of universities was assessed as direct requests, through search services, social networks, mail servers, as well as through referral links, and advertising traffic. The study showed that search engines and direct queries gave the maximum value for traffic. But the effectiveness of advertising to attract applicants is rather low, which indicates the insignificant role of university advertising and confirms the data of the survey in the construction of the Customer Journey Map

Structural and Optoelectronic Characterization of AgxCu1 x ZnSnSe4 solid solution

As the open circuit voltage in CZTSSe devices is believed to be limited by absorber band tailing caused by the exceptionally high density of Cu Zn disorder, replacing of Cu with Ag this density is predicted to drop. In this study, neutron diffraction and diffuse reflectance were applied to evaluate the crystal structure and optoelectronic properties of the Ag 1 x Cu x 2 ZnSnSe 4 solid solution ACZTSe . The results allow us to suggest that in spite of both end members of the solid solution being reported to crystallize in kesterite type structure, at least Ag 1 x Cu x 2 ZnSnSe4 with x 0.17 and 0.46 crystallize in the stannite type structure and thus block Cu Zn disorde

Structural characterization of off stoichiometric kesterite type Cu2ZnGeSe4 compound semiconductors from cation distribution to intrinsic point defect density

The substitution of Ge4 for Sn4 in Cu2ZnSn S,Se 4 CZTSSe kesterite type absorber layers for thin film solar cells has proven to enhance the opto electronic properties of the material. By cationic substitution, in general, the optical bandgap can be more readily designed for the purpose of bandgap engineering, and the substitution of Sn4 by Ge4 , in particular, widens the optical bandgap such that it can be employed both for photovoltaics as well as solar fuel quarrying by photocatalytic water splitting. This work is an experimental study of intrinsic point defects in off stoichiometric kesterite type Cu2ZnGeSe4 CZGSe by means of neutron powder diffraction. We revealed the existence of copper vacancies VCu , various cation antisite defects CuZn, ZnCu, ZnGe, CuGe as well as interstitials Cui, Zni in a wide range of off stoichiometric polycrystalline material synthesized by solid state reaction. In addition to the off stoichiometry type specific defects, Cu Zn disorder is always present in the kesterite type CZGSe phase. While compositional changes are clearly reflected by the tetragonal deformation c 2a, the lattice parameters a, c seem differently responding to point defect types and concentration variations, respectively. The CuGe antisite defect which is known to greatly deteriorate the opto electronic properties exists only in Cu rich CZGSe, but appears already in CZGSe with Cu Zn Ge amp; 8776;1. Furthermore we showed by diffuse reflectance hyperspectral imaging a widening of the energy bandgap in off stoichiometric kesterite type CZGSe with decreasing Cu Zn G

Routes to develop a [S]/([S]+[Se]) gradient in wide band-gap Cu2ZnGe(S,Se)4 thin-film solar cells

Wide band-gap kesterite-based solar cells are very attractive to be used for tandem devices as well as for semi-transparent photovoltaic cells. Here, Cu2ZnGe(S,Se)4 (CZGSSe) thin films have been grown by sulfurization of co-evaporated Cu2ZnGeSe4. The influence of a NaF precursor layer and of a Se capping film on CZGSSe absorbers and solar cells has been investigated. It has been found that the distribution of [S]/([S]+[Se]) through the CZGSSe absorber layer is strongly dependent on the Na content. Na promotes the diffusion of S towards the bulk of the absorber layer. Thicker NaF layers>6 nm lead to a higher S content in the bulk of the absorber layer, but to a decreased accumulation of sulphur at the surface, as detected by GIXRD, GD-OES, and Raman spectroscopy measurements. A relationship between Jsc, FF and Na-content supplied was found; higher Na content resulted in improved solar cell efficiencies. It has also been possible to modify the [S]/([S]+[Se])-gradient throughout the CZGSSe film by the absence of the Se capping layer, achieving devices with 2.7% performance and Eg = 2.0 eV. This work reveals two ways to control the [S]/([S]+[Se]) depth-profile to produce wide band gap CZGSSe absorber layers for efficient solar cells

Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy

OBJECTIVE: To evaluate efficacy and safety of lacosamide compared with placebo in painful diabetic polyneuropathy. RESEARCH DESIGN AND METHODS: Diabetic patients with at least moderate neuropathic pain were randomized to placebo or lacosamide 400 (in a slow or standard titration) or 600 mg/day over 6-week titration and 12-week maintenance periods. Primary efficacy criterion was intra-individual change in average daily Numeric Pain Rating Scale score from baseline to the last 4 weeks. RESULTS: For the primary end point, pain reduction was numerically but not statistically greater with lacosamide compared with placebo (400 mg/day, P = 0.12; 600 mg/day, P = 0.18). Both doses were significantly more effective compared with placebo over the titration (P = 0.03, P = 0.006), maintenance (P = 0.01, P = 0.005), and entire treatment periods (P = 0.03, P = 0.02). Safety profiles between titration schemes were similar. CONCLUSIONS: Lacosamide reduced neuropathic pain and was well tolerated in diabetic patients, but the primary efficacy criterion was not met, possibly due to an increased placebo response over the last 4 weeks.status: publishe

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background Liraglutide 3\ub70 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3\ub70 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2\ub77 times longer with liraglutide than with placebo (95% CI 1\ub79 to 3\ub79, p<0\ub70001), corresponding with a hazard ratio of 0\ub721 (95% CI 0\ub713\u20130\ub734). Liraglutide induced greater weight loss than placebo at week 160 (\u20136\ub71 [SD 7\ub73] vs 121\ub79% [6\ub73]; estimated treatment difference 124\ub73%, 95% CI 124\ub79 to 123\ub77, p<0\ub70001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3\ub70 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding Novo Nordisk, Denmark

A randomized, controlled trial of 3.0 mg of liraglutide in weight management

BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P&lt;0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P&lt;0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P&lt;0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONS In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.)